Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three and twelve months ended December 31, 2020.

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results

TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human Phase I clinical trial evaluating Amilo-5MER for the treatment of chronic inflammatory diseases.

Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER

TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, March 18, 2021, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter and year ended December 31, 2020.

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18

TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it is commencing an underwritten public offering of its...

Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares

TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced upcoming publication of a paper entitled "Aramchol...

Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3...

Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript

TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co.

Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co.

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Galmed (GLMD) Stock Stands Out in a Strong Industry

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic...

Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q4 2019 Results - Earnings Call Transcript

Allergan

CymaBay Therapeutics

Conatus Pharma

Intercept Pharma

Madrigal Pharmaceuticals

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

NASH Scorecard Year to Date: The Winners and the Losers

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript

Callon Petroleum

Sientra

Tellurian

Viking Therapeutics

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Healthy Upside Potential Seen in 5 More Stocks Trading Under $10

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates

Inovio Pharmaceuticals

La Jolla Pharmaceutical

MannKind

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

Galmed Pharmaceuticals delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

News for Galmed Pharmaceuticals Stock (GLMD)